https://www.avient.com/sites/default/files/2024-12/Terms and Conditions of Sale for Chile %28English and Spanish Translation%29.pdf
Seller warrants good
and clear title in the Product and that the Product
conforms at the time of shipment to Buyer a
Certificate of Analysis, a Certificate of Compliance,
or a Product Specification Sheet, if any such
document exists, or in any other specifications either
signed by Seller (“Specifications”).
Thereafter,
Buyer automatically approves the invoice.
license or approval.
https://www.avient.com/sites/default/files/2021-06/colormatrix-select-brochure.pdf
This unique automated
dispense system ensures that approved,
consistent and repeatable colors are
available to you, wherever and whenever you
need them.
Ultra-
fast availability of representative samples in your
target resin allows visualization, adjustment and
approval of colors to be completed within days
instead of weeks.
By visiting one of our Select facilities colors can
be created, developed and approved in as little
as 30 minutes.
https://www.avient.com/sites/default/files/2024-06/39913 - Ecert issued 14 Jun 24.pdf
Certificate - IATF 16949 - Avient Corporation - 596306 - 2806569 (2).pdf
https://www.avient.com/sites/default/files/2024-10/Avient_CodeConduct_2024_final2.pdf
Complete required compliance and ethics training and certifications.
If not, you need to identify
an approved member of management who can approve
and sign the contract in accordance with these rules.
In such cases, Avient
funds and resources may
be used but only when
permitted by law and with
the necessary approvals.
https://www.avient.com/sites/default/files/2023-07/Avient_CodeConduct_2023_USA.pdf
Complete required compliance and ethics training and
certifications.
If not, you need to
identify an approved member of management who
can approve and sign the contract in accordance
with these rules.
In such cases, Avient
funds and resources may be used but only when permitted
by law and with the necessary approvals.
https://www.avient.com/news/polyone-expands-healthcare-portfolio-biomerics’-specialty-medical-solutions
These highly biocompatible polymers will enhance our ability to help our customers accelerate speed-to-market, meet or exceed product performance requirements and navigate regulatory approvals more confidently,” said Mark Crist, president, PolyOne Distribution.
https://www.avient.com/investor-center/news/polyone-host-investor-conference-call
the time required to consummate the acquisition of Clariant's color and additive masterbatch business; the satisfaction or waiver of conditions in the purchase agreements; any material adverse changes in Clariant's color and additive masterbatch business; the ability to obtain required regulatory or other third-party approvals and consents and otherwise consummate the proposed acquisition of Clariant's color and additive masterbatch business; our ability to achieve the strategic and other objectives relating to the proposed acquisition of Clariant's color and additive masterbatch business, including any expected synergies; our ability to successfully integrate Clariant's color and additive masterbatch business and achieve the expected results of the acquisition of Clariant's color and additive masterbatch business, including, without limitation, the acquisition being accretive; disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; the effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; changes in polymer consumption growth rates and laws and regulations regarding plastics in jurisdictions where we conduct business; changes in global industry capacity or in the rate at which anticipated changes in industry capacity come online; fluctuations in raw material prices, quality and supply, and in energy prices and supply; production outages or material costs associated with scheduled or unscheduled maintenance programs; unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; an inability to raise or sustain prices for products or services; an ability to achieve or delays in achieving or achievement of less than the anticipated financial benefit from initiatives related to acquisitions and integration, working capital reductions, costs reductions and employee productivity goals; information systems failures and cyberattacks; and other factors affecting our business beyond our control, including, without limitation, changes in the general economy, changes in interest rates and changes in the rate of inflation.
https://www.avient.com/investor-center/news/polyone-announces-exercise-option-purchase-additional-common-shares
masterbatch business; the ability to obtain required regulatory or other third-party approvals and consents and otherwise consummate the acquisitions; our ability to achieve the strategic and other objectives relating to the acquisitions, including any expected synergies; our ability to successfully integrate
https://www.avient.com/investor-center/news/avient-completes-acquisition-dsm-protective-materials-dyneema
Factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to: disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; the effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks, including recessionary conditions; the current and potential future impact of the COVID-19 pandemic on our business, results of operations, financial position or cash flows, including without limitation, any supply chain and logistics issues; changes in polymer consumption growth rates and laws and regulations regarding plastics in jurisdictions where we conduct business; fluctuations in raw material prices, quality and supply, and in energy prices and supply; production outages or material costs associated with scheduled or unscheduled maintenance programs; unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; our ability to pay regular quarterly cash dividends and the amounts and timing of any future dividends; information systems failures and cyberattacks; amounts for cash and non-cash charges related to restructuring plans that may differ from original estimates, including because of timing changes associated with the underlying actions; our ability to successfully integrate the Avient Protective Materials business and achieve the expected results of the business, including without limitation, the acquisition being accretive; any material adverse changes in the business supporting the Distribution assets being sold; the ability to obtain required regulatory approvals and otherwise consummate the proposed sale of the Distribution business; our ability to achieve the strategic and other objectives relating to the Avient Protective Materials business and the proposed sale of the Distribution business; and other factors described in our Annual Report on Form 10-K for the year ended
https://www.avient.com/industries/healthcare/medical-devices-equipment/imaging-technology
Explore our solutions to help meet your design needs, performance criteria and regulatory approvals.